SPI Pharma

Abstract Purpose Lamotrigine therapy in pediatric epilepsy is constrained by the absence of age-appropriate dosage forms, as commercially available tablets...

By Philippe Tschopp This year´s CPHI Milan is over. Thousands of meetings, countless discussions and an impressive range of technologies...

Abstract Background/Objectives: The development of multifaceted excipients is a requirement of the pharmaceutical industry. This study aimed to develop a...

Wilmington, DE and Harleysville, PA | October 1, 2026 SPI Pharma, a global leader in pharmaceutical excipients, antacid actives, and...

WILMINGTON, DE — SEPTEMBER 29, 2026 SPI Pharma, a global developer of excipients, drug delivery technologies, vaccine adjuvants, and antacid...

Abstract The most relevant challenge concerning the semi-solid extrusion 3D printing (SSE) pharmaceutical application is the development of versatile inks...

Wilmington, Delaware - September 2026 SPI Pharma  announced that its strategic manufacturing partner, Q-Vant, has successfully achieved EXCiPACT certification, an...

This year CPHI Europe opens its doors in Milan at Fiera Milano. From 6th to 8th October you can have a...

FROM CHALLENGE TO TRIUMPH Formulating a 500 mg chewable Vitamin C tablet proved especially difficult due to the ingredient’s poor...

FROM CHALLENGE TO TRIUMPH Effervescent tablets pose unique formulation challenges — balancing tablet strength, dissolution, and appearance while managing large...